59
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Pharmacogenomic implications of the differential distribution of CYP3A5 metabolic phenotypes among Latin American populations

ORCID Icon & ORCID Icon
Pages 187-195 | Received 11 Jan 2024, Accepted 28 Feb 2024, Published online: 20 Mar 2024

References

  • Lamba JK , LinYS , SchuetzEG , ThummelKE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug Deliv. Rev.54(10), 1271–1294 (2002).
  • Lamba J , HebertJM , SchuetzEG , KleinTE , AltmanRB. PharmGKB summary: very important pharmacogene information for CYP3A5. Pharmacogenetics Genom. 22(7), 555–558 (2012).
  • Birdwell KA , DeckerB , BarbarinoJMet al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clin. Pharmacol. Ther.98(1), 19–24 (2015).
  • Pratt VM , CavallariLH , FulmerMLet al. CYP3A4 and CYP3A5 genotyping recommendations: a joint consensus recommendation of the Association for Molecular Pathology, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, and Pharmacogenomics Knowledgebase. J. Mol. Diagn.25(9), 619–629 (2023).
  • Kuehl P , ZhangJ , LinYet al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet.27(4), 383–391 (2001).
  • Hustert E , HaberlM , BurkOet al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics11(9), 773–779 (2001).
  • Auton A , BrooksLD , DurbinRMet al. 1000 Genomes Project Consortium; a global reference for human genetic variation. Nature526(7571), 68–74 (2015).
  • Suarez-Kurtz G , VargensDD , SantoroABet al. Global pharmacogenomics: distribution of CYP3A5 polymorphisms and phenotypes in the Brazilian population. PLOS ONE9(1), e83472 (2014).
  • Debortoli G , de AraujoGS , Fortes-LimaC , ParraEJ , Suarez-KurtzG. Identification of ancestry proportions in admixed groups across the Americas using clinical pharmacogenomic SNP panels. Sci. Rep.11(1), 1007 (2021).
  • Pena SD , DiPietro G , Fuchshuber-MoraesMet al. The genomic ancestry of individuals from different geographical regions of Brazil is more uniform than expected. PLOS ONE6(2), e17063 (2011).
  • Harrell FE . Regression Modeling Strategies with Applications to Linear Models, Logistic Regression, and Survival Analysis.SpringerNY, USA (2002).
  • R Development Core Team . R: A Language and Environment for Statistical Computing.R Foundation for Statistical ComputingVienna, Austria (2023).
  • Tonk ECM , GurwitzD , Maitland-vander Zee AH , JanssensACJW. Assessment of pharmacogenetic tests: presenting measures of clinical validity and potential population impact in association studies. Pharmacogenomics J. 17(4), 386–392 (2017).
  • Rojas L , NeumannI , HerreroMJet al. Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies. Pharmacogenomics J. 15(1), 38–48 (2015).
  • Cohen J . Statistical Power Analysis for the Behavioral Sciences (Second Edition).Lawrence Erlbaum Associates PublishersNJ, USA (1988).
  • Wright S . Variability within and among Natural Populations.University of Chicago Press, IL, USA (1978).
  • Bonifaz-Peña V , ContrerasAV , StruchinerCJet al. Exploring the distribution of genetic markers of pharmacogenomics relevance in Brazilian and Mexican populations. PLOS ONE9(11), e112640 (2014).
  • Fohner AE , DaltonR , SkagenKet al. Characterization of CYP3A pharmacogenetic variation in American Indian and Alaska Native communities, targeting CYP3A4*1G allele function. Clin. Transl. Sci.14(4), 1292–1302 (2021).
  • Santoro A , FelipeCR , Tedesco-SilvaHet al. Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients. Pharmacogenomics12(9), 1293–1303 (2011).
  • Cusinato DA , LacchiniR , RomaoEA , Moysés-NetoM , CoelhoEB. Relationship of CYP3A5 genotype and ABCB1 diplotype to tacrolimus disposition in Brazilian kidney transplant patients. Br. J. Clin. Pharmacol.78(2), 364–372 (2014).
  • Everton JBF , PatrícioFJB , FariaMSet al. CYP3A5 and PPARA genetic variants are associated with low trough concentration to dose ratio of tacrolimus in kidney transplant recipients. Eur. J. Clin. Pharmacol.77(6), 879–886 (2021).
  • Contreras-Castillo S , PlazaA , StojanovaJet al. Effect of CYP3A4, CYP3A5, MDR1 and POR genetic polymorphisms in immunosuppressive treatment in Chilean kidney transplanted patients. Front. Pharmacol.12, 674117 (2021).
  • García-Roca P , MedeirosM , ReyesHet al. CYP3A5 polymorphism in Mexican renal transplant recipients and its association with tacrolimus dosing. Arch. Med. Res.43(4), 283–287 (2012).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.